Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
Sensorion, a pioneering clinical-stage biotechnology company that specializes in gene therapies in the ear, announces the appointment of Khalil Barrage as Interim Chair of the Board. Mr. Barrage will replace Scott D. Myers, who has informed the Board that he will step down to manage other commitments, as he was recently appointed as Chief Executive Officer of Viridian Therapeutics Inc.
Mr Barrage has served on the Board of Sensorion for over three years, supporting with several capital raises and providing leadership on the Company’s evolution towards becoming a gene therapy-focused company. He has been a managing director at Invus Group, a major investor in Sensorion, for nearly 20 years, heading its Public Equity group and serves on the Boards of Elevate Bio, Onxeo, Orthobond and Protagenic Therapeutics. He is also a Board member of the Children of Armenia Fund and Solving Kids Cancer. Mr Barrage holds a BA from the American University of Beirut. Sensorion has commenced a search process to appoint a new independent Chair of the Board and will provide an update in due course.
Nawal Ouzren, Chief Executive Officer of Sensorion, commented: “Scott has been an extremely effective and engaged Chair at Sensorion and on behalf of the Board and management team, I would like to extend my sincere thanks and wish him well going forward. Khalil Barrage is a seasoned investment professional with decades of experience investing in and supporting private and public life sciences companies. We are delighted to have someone of his calibre and who knows the Company so well, steering the business as we evolve our focus into the promising area of gene therapies for the ear.”
Khalil Barrage commented: “I also would like to thank Scott for his immense contribution, he has provided expert leadership as we have moved into the next stage of development with a focus on gene therapy. Sensorion is a great Company with a highly compelling proposition for creating durable solutions to address inner ear disease. I’m very confident that the team can help steward its promising programme of gene therapy assets into clinical development.
“Sensorion is building an extremely high-quality leadership team, recently appointing David Lawrence as our Chief Financial Officer alongside Nawal. David has decades of experience in financing, capital markets and business development. This is the right team to move Sensorion and its innovative product candidates forward and I’m excited to be working with them.”
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more